Clinical Outcome of Beta-Tricalcium Phosphate Use for Bone Defects after Operative Treatment of Benign Tumors
10.4055/cios.2019.11.2.233
- Author:
Haksun CHUNG
1
;
Sanghyo KIM
;
So Hak CHUNG
Author Information
1. Department of Orthopedic Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea. shchung@kosin.ac.kr
- Publication Type:Original Article
- Keywords:
Beta-tricalcium phosphate;
Bone transplantation
- MeSH:
Allografts;
Bone Remodeling;
Bone Transplantation;
Humans;
Prospective Studies;
Transplants
- From:Clinics in Orthopedic Surgery
2019;11(2):233-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We investigated the clinical outcome in patients whose cavitary bone defects were treated with beta-tricalcium phosphate (β-TCP) after surgical removal of benign tumors. METHODS: Between March 2015 and December 2015, 20 patients who underwent operation for bone tumors were enrolled into this study and prospectively followed up for a median period of 28.1 months. RESULTS: When the radiographic sign of complete resorption was defined as greater than 50% resorption of the allograft material accompanied by bone remodeling until 12 months, 55% of patients had complete resorption. Positive correlation between the filling volume and time needed for complete resorption was not found (p = 0.184). CONCLUSIONS: Purified β-TCP could be a suitable choice as a bone graft substitute after the removal of benign bone tumors.
